NFL Biosciences
ALNFL – FR0014003XT0
Quotation from 06/28/2023 at 00:00
€ 2,630 0,00%
Following the exercise of BSA…
Photo credit NissierPictures
By Alexandra Saintpierre
Published on 06/29/2023 at 6:03 p.m.
The biopharmaceutical company NFL Biosciences has been informed of the exercise of 100,000 stock warrants (BSA) held by GB Holding, Gérard Leduc’s holding company, giving rise to the creation of 1 million new shares. GB Holding holds as of June 29, 2023, 850,000 shares representing 11.17% of the capital of NFL Biosciences and has undertaken to retain all of the shares held for a minimum period of 9 months.
Gérard Leduc is a recognized entrepreneur in the pharmaceutical sector, he notably founded, managed and sold Ethypharm, a European pharmaceutical laboratory specializing in pathologies of the Central Nervous System (CNS) and Hospital Injectables which had more than 800 employees. Since July 2018, GB Holding has held 100,000 BSA exercisable until July 2, 2023 at a price of 0.50 euro per share, one warrant giving the right to subscribe to 10 shares with a nominal value of 0.03 euro. Their exercise represents a cash contribution of €0.5 million for the Company and gives rise to the issue of 1 million new shares. GB Holding has made a lock-up commitment, with Invest Securities, relating to 850,000 shares subscribed within the framework of the exercise of the BSA, for 9 months following the date of settlement-delivery of the new shares, i.e. until March 31 2024. The new shares were issued on June 29 by the company and immediately assimilated to the existing shares (ISIN code FR0014003XT0).
“I am thrilled to continue contributing to the success of NFL Biosciences. Addiction treatment products have always been of great interest to me. NFL-101, for smoking cessation, is a potentially revolutionary product with a whole new mechanism of action. It could change the way this addiction is treated so far”, comments Mr. Leduc on the occasion of the exercise of his BSA.
2023-06-29 16:03:00
#Holding #climbs #capital
